Literature DB >> 19759525

Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those excreted by the kidney.

Balthasar L Hug1, Daniel J Witkowski, Colin M Sox, Carol A Keohane, Diane L Seger, Catherine Yoon, Michael E Matheny, David W Bates.   

Abstract

Medication errors in patients with reduced creatinine clearance are harmful and costly; however, most studies have been conducted in large academic hospitals. As there are few studies regarding this issue in smaller community hospitals, we conducted a multicenter, retrospective cohort study in six community hospitals (100 to 300 beds) to assess the incidence and severity of adverse drug events (ADEs) in patients with reduced creatinine clearance. A chart review was performed on adult patients hospitalized during a 20-month study period with serum creatinine over 1.5 mg/dl who were exposed to drugs that are nephrotoxic or cleared by the kidney. Among 109,641 patients, 17,614 had reduced creatinine clearance, and in a random sample of 900 of these patients, there were 498 potential ADEs and 90 ADEs. Among these ADEs, 91% were preventable, 51% were serious, 44% were significant, and 4.5% were life threatening. Of the potential ADEs, 54% were serious, 44% were significant, 1.6% were life threatening, and 96.6% were not intercepted. All 82 preventable events could have been intercepted by renal dose checking. Our study shows that ADEs were common in patients with impaired kidney function in community hospitals, and many appear potentially preventable with renal dose checking.

Entities:  

Mesh:

Year:  2009        PMID: 19759525     DOI: 10.1038/ki.2009.353

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  30 in total

1.  Management of drug toxicity in patients with renal insufficiency.

Authors:  Claudio Ponticelli; Giorgio Graziani
Journal:  Nat Rev Nephrol       Date:  2010-06       Impact factor: 28.314

2.  Impact of vendor computerized physician order entry in community hospitals.

Authors:  Alexander A Leung; Carol Keohane; Mary Amato; Steven R Simon; Michael Coffey; Nathan Kaufman; Bismarck Cadet; Gordon Schiff; Eyal Zimlichman; Diane L Seger; Catherine Yoon; Peter Song; David W Bates
Journal:  J Gen Intern Med       Date:  2012-01-21       Impact factor: 5.128

Review 3.  Patient and facility safety in hemodialysis: opportunities and strategies to develop a culture of safety.

Authors:  Renee Garrick; Alan Kliger; Beth Stefanchik
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 8.237

4.  The missing piece: Clinical pharmacists enhancing the interprofessional nephrology clinic model.

Authors:  Chelsea E Hawley; Laura K Triantafylidis; Julie M Paik
Journal:  J Am Pharm Assoc (2003)       Date:  2019-06-21

Review 5.  Computerized decision support systems: improving patient safety in nephrology.

Authors:  Jamison Chang; Claudio Ronco; Mitchell H Rosner
Journal:  Nat Rev Nephrol       Date:  2011-04-19       Impact factor: 28.314

6.  Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults.

Authors:  Alex Secora; G Caleb Alexander; Shoshana H Ballew; Josef Coresh; Morgan E Grams
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

Review 7.  Reducing hospital readmissions in patients with end-stage kidney disease.

Authors:  Anna T Mathew; Giovanni F M Strippoli; Marinella Ruospo; Steven Fishbane
Journal:  Kidney Int       Date:  2015-10-14       Impact factor: 10.612

8.  Patient-reported and actionable safety events in CKD.

Authors:  Jennifer S Ginsberg; Min Zhan; Clarissa J Diamantidis; Corinne Woods; Jingjing Chen; Jeffrey C Fink
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

9.  Adverse drug events during AKI and its recovery.

Authors:  Zachary L Cox; Allison B McCoy; Michael E Matheny; Gautam Bhave; Neeraja B Peterson; Edward D Siew; Julia Lewis; Ioana Danciu; Aihua Bian; Ayumi Shintani; T Alp Ikizler; Erin B Neal; Josh F Peterson
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 8.237

10.  Use of renal risk drugs in patients with renal impairment.

Authors:  Hilde Holm; Kirsti Bjerke; Lone Holst; Liv Mathiesen
Journal:  Int J Clin Pharm       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.